Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 242 participants.
Also called NCT02606357
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 242 participants
- Sponsor
- Registry
-
NCT02606357
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Jordan
- Registry status
- Completed
Technical summary
Registry record NCT02606357. Allocation not applicable; no masking; primary purpose treatment. Start 2015-11-22 (actual); primary completion 2017-11-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan
- Acronym
- NEWLAN
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- INSULIN GLARGINE
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct02606357- Content hash
a237f8139d2bc74a28cccb3ef589e5d277d5f00d2e814b4b19fae438e345b4b2